
Ryan Haumschild, PharmD, MS, MBA, drives a conversation regarding the epidemiology of metastatic colorectal cancer (mCRC) in the US.
Ryan Haumschild, PharmD, MS, MBA, drives a conversation regarding the epidemiology of metastatic colorectal cancer (mCRC) in the US.
Medical experts discuss the financial impact of early detection in colorectal cancer.
Experts explore the importance of early detection of metastatic colorectal cancer.
Panelists highlight challenges facing both patients and caregivers associated with colorectal cancer treatment.
Collaborative care from medical and surgical oncologists as well as supportive care teams provides an optimal treatment environment for patients facing mCRC diagnosis.
Medical experts explore the main treatment goals and modalities beyond pharmacotherapies for mCRC treatment, and discuss targetable mutations being explored in mCRC.
Ben George, MD, and John L. Marshall, MD, analyze the use of targeted therapies as an alternative to chemotherapy in mCRC treatment.
Medical experts discuss treatment-related toxicity management strategies in mCRC.
The panelists examine a recent FDA approval that provides new opportunities for effective combination strategies in mCRC treatment.
David Fenstermacher, PhD, provides insights regarding key advancements and pipeline treatments for metastatic colorectal cancer.
Medical experts discuss precision medicine and targeted therapies driving the management of metastatic colorectal cancer treatment.
The panelists discuss breakthrough technologies that are revolutionizing mCRC diagnosis.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.